Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Bays

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Drug Discovery Today. Technologies|July 2, 2014
Yeast as a budding technology in target validationNathan Bays, Jonathan Margolis
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2005
Reticulocyte lysate as a model system to study endoplasmic reticulum membrane protein degradationEric Carlson, Nathan Bays, Larry David, et al.
Journal of Biomolecular Screening|May 1, 2009
Development of a cell-based assay for measurement of c-Met phosphorylation using AlphaScreen technology and high-content imaging analysisNadya Smotrov, Anjili Mathur, Ilona Kariv, et al.
Bioorganic & Medicinal Chemistry Letters|April 14, 2012
Triazoloamides as potent γ-secretase modulators with reduced hERG liabilityChristian Fischer, Susan L Zultanski, Hua Zhou, et al.
Physiological Reports|October 9, 2024
Electrical stimulation of biofidelic engineered muscle enhances myotube size, force, fatigue resistance, and induces a fast-to-slow-phenotype shiftIsabella Pallotta, Michael J Stec, Brian Schriver, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2006
3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitorsAlexey Rivkin, Yoona R Kim, Mark T Goulet, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 15, 2017
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 InhibitorFiona Elwood, David J Witter, Jennifer Piesvaux, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2011
Triazoles as γ-secretase modulatorsChristian Fischer, Susan L Zultanski, Hua Zhou, et al.
Journal of Medicinal Chemistry|November 21, 2017
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic PropertiesTony Siu, Jason Brubaker, Peter Fuller, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Drug Discovery Today. Technologies|July 2, 2014
Yeast as a budding technology in target validationNathan Bays, Jonathan Margolis
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2005
Reticulocyte lysate as a model system to study endoplasmic reticulum membrane protein degradationEric Carlson, Nathan Bays, Larry David, et al.
Journal of Biomolecular Screening|May 1, 2009
Development of a cell-based assay for measurement of c-Met phosphorylation using AlphaScreen technology and high-content imaging analysisNadya Smotrov, Anjili Mathur, Ilona Kariv, et al.
Bioorganic & Medicinal Chemistry Letters|April 14, 2012
Triazoloamides as potent γ-secretase modulators with reduced hERG liabilityChristian Fischer, Susan L Zultanski, Hua Zhou, et al.
Physiological Reports|October 9, 2024
Electrical stimulation of biofidelic engineered muscle enhances myotube size, force, fatigue resistance, and induces a fast-to-slow-phenotype shiftIsabella Pallotta, Michael J Stec, Brian Schriver, et al.
Bioorganic & Medicinal Chemistry Letters|June 21, 2006
3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitorsAlexey Rivkin, Yoona R Kim, Mark T Goulet, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 15, 2017
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 InhibitorFiona Elwood, David J Witter, Jennifer Piesvaux, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2011
Triazoles as γ-secretase modulatorsChristian Fischer, Susan L Zultanski, Hua Zhou, et al.
Journal of Medicinal Chemistry|November 21, 2017
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic PropertiesTony Siu, Jason Brubaker, Peter Fuller, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Pageof 2